



Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	09/757,555
				Filing Date	January 9, 2001
				First Named Inventor	Levon M. KHACHIGIAN
				Art Unit	1633
				Examiner Name	J. Epps-Ford
Sheet	1	of	2	Attorney Docket Number	529282000220

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author ( in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
JE	1.	Adamis, A.P. et al. (1999). "Angiogenesis and Ophthalmic Disease," <i>Angiogenesis</i> 3:9-14.		
JE	2.	Bhushan, M. et al. (2002). "Topical Review: Recent Advances in Cutaneous Angiogenesis," <i>British Journal of Dermatology</i> 147:418-425.		
JE	3.	Dichtl, W. et al. (2003). "HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in Human Endothelial and Vascular Smooth Muscle Cells," <i>Arterioscler. Thromb. Vasc. Biol.</i> 23:58-63.		
JE	4.	Fahmy, R.G. et al. (2004). "Locked Nucleic Acid Modified DNA Enzymes Targeting Early Growth Response-1 Inhibit Human Vascular Smooth Muscle Cell Growth," <i>Nucleic Acids Research</i> 32(7):2281-2285.		
JE	5.	Ferrara, N. et al. (June 2003). "The Biology of VEGF and Its Receptors," <i>Nature Medicine</i> 9(6):669-676.		
JE	6.	Hofer, G. et al. (November 8, 1996). "Transcription Factor Egr-1 Regulates Glomerular Mesangial Cell Proliferation," <i>The Journal of Biological Chemistry</i> 271(45):28306-28310.		
JE	7.	Ito, Y. et al. (October 15, 2003). "Inhibition of Angiogenesis and Vascular Leakiness by Angiopoietin-Related Protein 4," <i>Cancer Research</i> 63:6651-6657.		
JE	8.	Janssen, Y.M.W. et al. (1997). "Differential Induction of c-fos, c-jun, and Apoptosis in Lung Epithelial Cells Exposed to ROS or RNS," <i>Lung Cell. Mol. Physiol.</i> 17:L789-L796.		
JE	9.	Krzystolik, M.G. et al. (March 2002). "Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti-Vascular Endothelial Growth Factor Antibody Fragment," <i>Arch. Ophthalmol.</i> 120:338-346.		
JE	10.	Kukita, T. et al. (1997). "Regulation of Osteoclastogenesis by Antisense Oligodeoxynucleotides Specific to Zinc Finger Nuclear Transcription Factors Egr-1 and WT1 in Rat Bone Marrow Culture System," <i>Endocrinology</i> 138(10):4384-4389.		
JE	11.	Kurreck, J. et al. (March 1, 2002). "Comparative Study of DNA Enzymes and Ribozymes Against the Same Full-Length Messenger RNA of the Vanilloid Receptor Subtype 1," <i>The Journal of Biological Chemistry</i> 277(9):7099-7107.		
JE	12.	Leenders, W. et al. (April 2002). "Design of a Variant of Vascular Endothelial Growth Factor-A (VEGF-A) Antagonizing KDR/Flk-1 and Flt-1," <i>Laboratory Investigation</i> 82(4):473-481.		
JE	13.	Malve, R.E. et al. (1995). "Tumor-Promoting Activity of 2,4-Dinitrofluorobenzene," <i>Int. J. Cancer</i> 60:545-553.		

Examiner Signature	/Janet Epps Ford/	Date Considered	05/12/2006
-----------------------	-------------------	--------------------	------------

pa-1015317

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/757,555
				Filing Date	January 9, 2001
				First Named Inventor	Levon M. KHACHIGIAN
				Art Unit	1633
				Examiner Name	J. Epps-Ford
Sheet	2	of	2	Attorney Docket Number	529282000220

JE	14.	Mitchell, A. et al. (2004). "Inhibition of Human Breast Carcinoma Proliferation, Migration, Chemoinvasion and Solid Tumour Growth by DNazymes Targeting the Zinc Finger Transcription Factor EGR-1," <i>Nucleic Acids Research</i> 32(10):3065-3069.
JE	15.	Momiyama, N. et al. (August 1996). "Suppression of <i>c-jun</i> by Antisense Oligonucleotides Inhibits Cell Adhesion but not Respiratory Burst during Phorbol Ester-induced Differentiation of U937 Human Monoblastic Cells," <i>Cell Growth &amp; Differentiation</i> 7:1005-1012.
JE	16.	Nakamura, H. (2002). "Introduction of DNA Enzyme for Egr-1 Into Tubulointerstitial Fibroblasts by Electroporation Reduced Interstitial $\alpha$ -smooth Muscle Actin Expression and Fibrosis in Unilateral Ureteral Obstruction (UUO) Rats," <i>Gene Therapy</i> 9:495-502.
JE	17.	Nguyen, H.Q. et al. (January 29, 1993). "The Zinc Finger Transcription Factor Egr-1 Is Essential for and Restricts Differentiation Along the Macrophage Lineage," <i>Cell</i> 72:197-209.
JE	18.	Pan, W-H. et al. (2004). "Identification of Efficient Cleavage Sites in Long-Target RNAs" Chapter 9 In <i>Methods in Molecular Biology: Ribozymes and siRNA Protocols</i> , Second Edition, Sioud, M. ed., Humana Press, Inc.: Totowa, NJ, 252:125-144.
JE	19.	Ross, R. (January 14, 1999). "Atherosclerosis - An Inflammatory Disease," <i>The New England Journal of Medicine</i> 340(2):115-126.
JE	20.	Santoro, S.W. et al. (April 1997). "A General Purpose RNA-Cleaving DNA Enzyme," <i>Proc. Natl. Acad. Sci. USA</i> 94:4262-4266.
JE	21.	Schärer, L.J. et al. (December 2003). "Approaches for the Sequence-Specific Knockdown of mRNA," <i>Nature Biotechnology</i> 21(12):1457-1465.
JE	22.	Sells, S.F. et al. (February 1995). "The Zinc Finger Transcription Factor EGR-1 Impedes Interleukin-1-Inducible Tumor Growth Arrest," <i>Molecular and Cellular Biology</i> 15(2):682-692.
JE	23.	Suggs, S.V. et al. (July 25, 1990). "cDNA Sequence of the Human Cellular Early Growth Response Gene Egr-1," <i>Nucleic Acids Research</i> 18(14):4283.
JE	24.	van Nieuw Amerongen, G.P. et al. (2003). "Targets for Pharmacological Intervention of Endothelial Hyperpermeability and Barrier Function," <i>Vascular Pharmacology</i> 39:257-272.
JE	25.	Wang, N. et al. (2001). "Adenovirus-Mediated Overexpression of Dominant-Negative Mutant of c-Jun Prevents Intercellular Adhesion Molecule-1 Induction by LDL," <i>Arterioscler. Thromb. Vasc. Biol.</i> 21:1414-1420.
JE	26.	Yamada, M. et al. (2003). "Molecular Mechanism and Role of Endothelial Monocyte Chemoattractant Protein-1 Induction by Vascular Endothelial Growth Factor," <i>Arterioscler. Thromb. Vasc. Biol.</i> 23:1996-2001.
JE	27.	Yokota, T. et al. (2004). "siRNA-Based Inhibition Specific for Mutant SOD1 with Single Nucleotide Alteration in Familial ALS, Compared with Ribozyme and DNA Enzyme," <i>Biochemical and Biophysical Research Communications</i> 314:283-291.
JE	28.	Zhang, G. et al. (May 5, 2004). "Effect of Deoxyribozymes Targeting c-Jun on Solid Tumor Growth and Angiogenesis in Rodents," <i>Journal of the National Cancer Institute</i> 96(9):683-696.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Janet Epps Ford/	Date Considered	05/12/2006
--------------------	-------------------	-----------------	------------

pa- 1015317